Italia, Jagdishbhai L and Sharp, Andrew and Carter, Katharine C and Warn, Peter and Kumar, M N V Ravi (2011) Peroral amphotericin B polymer nanoparticles lead to comparable or superior in vivo antifungal activity to that of intravenous Ambisome® or Fungizone™. PLoS One, 6 (10). e25744.Full text not available in this repository. (Request a copy from the Strathclyde author)
Despite advances in the treatment, the morbidity and mortality rate associated with invasive aspergillosis remains unacceptably high (70-90%) in immunocompromised patients. Amphotericin B (AMB), a polyene antibiotic with broad spectrum antifungal activity appears to be a choice of treatment but is available only as an intravenous formulation; development of an oral formulation would be beneficial as well as economical.
|Keywords:||polymer nanoparticles, antifungal activity , amphotericin B polymer nanoparticles, Therapeutics. Pharmacology|
|Subjects:||Medicine > Therapeutics. Pharmacology|
|Department:||Faculty of Science > Strathclyde Institute of Pharmacy and Biomedical Sciences|
?? 120 ??
|Depositing user:||Pure Administrator|
|Date Deposited:||16 Dec 2011 05:21|
|Last modified:||12 Jun 2013 14:34|
Actions (login required)